WallStreetZenWallStreetZen

NASDAQ: BLSM
Blossomhill Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BLSM

Based on 4 analysts offering 12 month price targets for Blossomhill Therapeutics Inc

Min Forecast
$28.00+41.77%
Avg Forecast
$33.25+68.35%
Max Forecast
$40.00+102.53%

Should I buy or sell BLSM stock?

Based on 4 analysts offering ratings for Blossomhill Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BLSM's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BLSM as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their BLSM stock forecasts and price targets.

BLSM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-21
lockedlocked$00.00+00.00%2026-09-21Find Out Why
lockedlocked$00.00+00.00%2026-09-01
lockedlocked$00.00+00.00%2026-09-01
lockedlocked$00.00+00.00%2026-09-01

1 of 1

Forecast return on equity

Is BLSM forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is BLSM forecast to generate an efficient return on assets?

Company
-90.37%
Industry
-4.33%
BLSM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BLSM earnings per share forecast

What is BLSM's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$3.90
Avg 2 year Forecast
-$3.37
Avg 3 year Forecast
-$3.53

BLSM revenue forecast

What is BLSM's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BLSM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BLSM$19.75$33.25+68.35%Strong Buy
OCS$9.27$36.67+295.54%Strong Buy
AURA$6.00$21.00+250.00%Buy
IBO$5.69N/AN/A
CRMD$7.85$15.17+93.21%Buy
View Top Biotech Stocks

Blossomhill Therapeutics Stock Forecast FAQ

Is Blossomhill Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BLSM) stock is to Strong Buy BLSM stock.

Out of 4 analysts, 3 (75%) are recommending BLSM as a Strong Buy, 1 (25%) are recommending BLSM as a Buy, 0 (0%) are recommending BLSM as a Hold, 0 (0%) are recommending BLSM as a Sell, and 0 (0%) are recommending BLSM as a Strong Sell.

If you're new to stock investing, here's how to buy Blossomhill Therapeutics stock.

What is BLSM's earnings growth forecast for 2026-2028?

(NASDAQ: BLSM) Blossomhill Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.61%.

Blossomhill Therapeutics's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast BLSM's earnings for 2026 to be -$123,977,038, with the lowest BLSM earnings forecast at -$134,876,083, and the highest BLSM earnings forecast at -$103,126,137. On average, 7 Wall Street analysts forecast BLSM's earnings for 2027 to be -$107,051,574, with the lowest BLSM earnings forecast at -$133,318,622, and the highest BLSM earnings forecast at -$87,774,026.

In 2028, BLSM is forecast to generate -$112,175,301 in earnings, with the lowest earnings forecast at -$134,564,591 and the highest earnings forecast at -$81,099,195.

What is BLSM's revenue growth forecast for 2026-2028?

(NASDAQ: BLSM) Blossomhill Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 43.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.28%.

Blossomhill Therapeutics's revenue in 2026 is N/A.On average, 5 Wall Street analysts forecast BLSM's revenue for 2026 to be $0, with the lowest BLSM revenue forecast at $0, and the highest BLSM revenue forecast at $0. On average, 5 Wall Street analysts forecast BLSM's revenue for 2027 to be $0, with the lowest BLSM revenue forecast at $0, and the highest BLSM revenue forecast at $0.

In 2028, BLSM is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BLSM's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: BLSM) forecast ROA is -90.37%, which is lower than the forecast US Biotechnology industry average of -4.33%.

What is BLSM's Price Target?

According to 4 Wall Street analysts that have issued a 1 year BLSM price target, the average BLSM price target is $33.25, with the highest BLSM stock price forecast at $40.00 and the lowest BLSM stock price forecast at $28.00.

On average, Wall Street analysts predict that Blossomhill Therapeutics's share price could reach $33.25 by Sep 21, 2027. The average Blossomhill Therapeutics stock price prediction forecasts a potential upside of 68.35% from the current BLSM share price of $19.75.

What is BLSM's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BLSM) Blossomhill Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that BLSM's EPS will be -$3.90 for 2026, with the lowest EPS forecast at -$4.24, and the highest EPS forecast at -$3.24. On average, analysts forecast that BLSM's EPS will be -$3.37 for 2027, with the lowest EPS forecast at -$4.19, and the highest EPS forecast at -$2.76. In 2028, BLSM's EPS is forecast to hit -$3.53 (min: -$4.23, max: -$2.55).

What is BLSM's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: BLSM) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.